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Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes 
Introduction
Aplastic anemia (AA) and myelodysplasia (MDS) are bone marrow (BM) failure syndromes in which impaired hematopoiesis results in single or multilineage cytopenias. AA usually affects younger patients. On presentation the marrow is hypocellular, the morphology of residual hematopoietic precursors is normal in AA, and cytogenetics shows normal chromosomes. Marrow failure in AA is usually secondary to an immunologic mechanism, and most patients respond to immunosuppressive therapies (IST) 1 . In contrast, MDS affects older patients. Marrow cellularity in MDS is often normal or increased, and dysmorphic changes are characteristic. Chromosomal defects are frequent in MDS. Despite these general differences, diagnostic confusion often arises. About 20% of MDS patients present with a hypocellular marrow, as in AA, and cytogenetics are normal in as many as 50% of MDS cases 2 . As the treatment toxicities and the long-term outcomes between AA and MDS differ substantially, a correct diagnosis at presentation is desirable for proper management.
Although bone marrow failure has been extensively investigated, little is known about the cytokines and chemokines in the blood. Cytokines and chemokines are soluble low-molecular-weight proteins secreted by immune cells that mediate inflammatory responses and regulate hematopoiesis by modulating bone marrow microenvironment.
Some are essential for the viability, proliferation and differentiation of hematopoietic stem cells. In vitro, monolayers of marrow-adherent cells, including fibroblasts, endothelial cells, adipocytes, and macrophages, produce a variety of cytokines, which include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage 4 colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), and stem cell factor (SCF), either constitutively or after stimulation with IL-1 or tumour necrosis factor-α (TNF-α) 3, 4 .
To date, measurements of soluble circulating mediating factors in marrow failure have been limited largely to one or two cytokines in AA 5-9 and MDS 10, 11 . Because of the complex array of proteins involved in an immune response, the measurement of a single cytokine is likely insufficient to assess alterations in disease. We conducted a comprehensive analysis of 31 cytokines, chemokines, and growth factors in the plasma of healthy volunteers, AA, and MDS patients. We describe differences in the cytokine profiles between those with marrow failure and healthy volunteers and propose a cytokine signature that might help to distinguish AA from hypocellular MDS.
Design and methods
Written informed consent from subjects was obtained in accordance with protocols approved by the Institutional Review Board of the National Heart, Lung, and Blood Institute (Bethesda, MD) and the Cleveland Clinic Foundation (Cleveland, OH).
Severe AA (SAA) was defined according to previous report 12 . Healthy controls and patients' characteristics are summarized in supplementary Table   S1 .
Plasma was obtained by centrifugation of heparinized peripheral blood and stored in aliquots at -80ºC until analysis. The following cytokines and growth factors were 
Results and Discussion
Due to the significant age difference between AA and MDS patients, we divided healthy controls into two groups: < 55 years of age (n=29) and ≥ 55 years (n=19), to better match the ages of AA and MDS patients, respectively. As shown in Due to the heterogeneity of MDS, we investigated variations of cytokine levels in different subgroups (Supplementary Figure S1) . Among the MDS subtypes ( Figure   S1A ), CCL5 and EGF were lower in RCMD and RAEB patients compared to those with RA-RS. CXCL5 was lower in RCMD and RAEB than in 5q-, it appeared that the levels of CCL5, EGF, and CXCL5 in different subtypes were proportional to the platelet counts they had. In high-risk MDS, decreased levels of CXCL5 (p < 0.01), CCL5 (p < 0.001), CD40L (p < 0.01), EGF (p < 0.01), and VEGF (p < 0.05) and an elevated level of CCL4 (p < 0.05) were observed compared to low-risk MDS ( Figure   S1B ). We then studied variations of cytokine levels in MDS patients with different marrow cellularity ( Figure S1C ), most cytokine levels were again similar, with the exception of Tpo, which was higher in hypocellular compared to hypercellular marrow (p < 0.05).
To determine if the cytokines that were decreased or increased in AA (compared to healthy controls) changed after IST, levels were measured before, at 3 and 6 months after ATG and CsA in 8 patients who were hematologic responders ( Figure 3 ).
Response was defined as no longer meeting criteria for SAA and was determined at 3 and 6 months following ATG 16 . Statistically significant increases of CD40L, CXCL5, CCL5, EGF, and VEGF were present at 6 months after IST compared to pre-treatment 9 levels. An increase was not seen for CCL11 and CXCL11 after IST. Tpo and G-CSF levels that were elevated in AA decreased after IST. Of the remaining cytokines that
were not different in untreated AA compared to healthy controls, no difference was noted after IST compared to pre-treatment levels, with the exception of CXCL10. In an additional three AA patients who were non-responders to IST, no changes of cytokines were observed at 3 and 6 months post treatment (data not shown).
To determine if higher Tpo levels observed in AA patients were a consequence of a lower platelet count, Tpo levels between AA and MDS patients with comparable low platelet counts were evaluated (platelet count on the day of the plasma collection in all patients). In patients with a platelet count < 40 × 10 9 /L, Tpo levels were higher in In summary, we show that differences in cytokine profiles exist between AA and MDS, suggesting differences in pathophysiology. More importantly, despite similar clinical presentations, differences in cytokine profiles were also present between AA and hypocellular MDS. Future studies focusing on those cytokines that differed significantly between these two entities (for example Tpo and CCL3) should define those relevant for laboratory discrimination and potentially provide an important tool in clinical practice. A more targeted evaluation of these cytokines using standard assays such as an ELISA could be more widely adopted when evaluating these cases and aid in proper diagnosis and management.
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